Table 3: Clinical and laboratory features of 97 MPNs patients stratified by TET2 status.

TET2-positive MPN ( )TET2-negative MPN ( ) value

Diagnosis
 MPN-U ( )3 (37.5%)5/8 (62.5%)
 ET ( )2 (3.6%)53 (96.4%)0.005
 PV ( )2 (8.0%)23 (92%)
 IMF ( )09
Median age, years (range)71 (43–76)65.5 (25–89)0.57
Follow-up months, median (range)38.6 (13.3–130)54.2 (4.3–195.7)0.38
Hb, g/100 mL (range)16.1 (13.3–19.9)15.2 (11.1–21.5)0.22
WBC × 109/L (range)6.86 (5.4–12.4)8.56 (1.7–19.6)0.3
Monocytes × 109/L (range)0.3 (0.1–1.15)0.45 (0.02–0.9)0.45
Plt × 109/L (range)476 (134–849)629 (149–1750)0.02
JAK 2 V617F (%)6/7 (85.7)66/90 (73.3)0.78
JAK 2 V617F burden median % (range)24 (5–65)25 (5–90)0.99
EEC (%)4/7 (57.1)71/90 (78.8)0.39
CFU-MK (%)1/7 (14.2)57/90 (63.3)0.01
CD34 + SP × 109/L (range)0.021 (0.0103–0.273)0.03 (0.0015–0.61)0.89
CD34 + SP (%) (range)0.03 (0.02–0.35)0.035 (0.0015–0.56)0.43
Bone marrow cellularity % (range)50 (30–80)50 (20–98)0.96
Single cytogenetic abnormality ( )0/75/90 (5.5)0.49
Complex karyotype ( )0/71/90 (1.1)
Trisomy ( )0/71/90 (1.1)
Pruritus ( )2/721/90 0.88
Palpable splenomegaly ( )2/737/900.8
Splenic square cm2 (range)40 (31–105)42 (25–200)0.45
Arterial thromboses ( )1/721/900.43
Venous thromboses ( )2/77/90
Spontaneous haemorrhage ( )0/7 2/90 0.58
Posttraumatic haemorrhage ( )0/7 2/90
Cytoreductive treatment ( )7/7 86/90 0.66